Abbott to Acquire Walk Vascular to Bolster its Peripheral Vascular Offerings
Shots:
- The acquisition will accelerate Abbott's vascular portfolio with the addition of Walk Vascular's peripheral thrombectomy systems to treat patients with peripheral blood clots
- Walk Vascular's JETi & JETi AIO peripheral thrombectomy systems are aspiration systems for the removal of intravascular clots. The systems are supported by RWE- and Walk is currently enrolling ~250 patients in the US and EU in the JETi Registry
- Additionally- both systems have received 510(k) clearance from the FDA for breaking soft emboli and thrombus from the peripheral vasculature to reduce the risk of dislodged clots. The systems also received a CE Mark in the EU and approvals in other countries
| Ref: Abbott | Image:Abbott
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com